Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344

Bibliography

• Smith RC, Lin BK. Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care 2013;7(4):352-60
   PubMed Web of Science ®Google Scholar
• MCPherron AC, Lee SJ. Double muscling in cattle due to mutations in the myostatin gene. Proc Natl Acad Sci USA 1997;94(23):12457
   PubMed Web of Science ®Google Scholar
• Lee S-J. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunol Endocr Metab Agents Med Chem 2010;10:183-94
   PubMedGoogle Scholar
• Cash JN, Rejon CA, McPherron A, et al. The structure of myostatin:follistatin 288: insights into receptor utilization and heparin binding. EMBO J 2009;28(17):2662-76
   PubMed Web of Science ®Google Scholar
• Cash JN, Angerman EB, Keutmann HT, Thompson TB. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism. Mol Endocrinol 2012;26(7):1167-78
   PubMedGoogle Scholar
• Lee S, McPherron A. Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 2001;98(16):9306-11
   PubMed Web of Science ®Google Scholar
• Langley B. Myostatin inhibits myoblast differentiation by down-regulating MyoD expression. J Biol Chem 2002;277(51):49831-40
   PubMed Web of Science ®Google Scholar
• Thomas M, Langley B, Berry C, et al. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J Biol Chem 2000;275(51):40235-43
   PubMed Web of Science ®Google Scholar
• Elliott B, Renshaw D, Getting S, Mackenzie R. The central role of myostatin in skeletal muscle and whole body homeostasis. Acta Physiol 2012;205(3):324-40
   PubMed Web of Science ®Google Scholar
• Thies RS, Chen T, Davies MV, et al. GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors 2001;18(4):251-9
   PubMed Web of Science ®Google Scholar
• Hill JJ, Davies MV, Pearson AA, et al. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem 2002;277(43):40735-41
   PubMed Web of Science ®Google Scholar
• Hill JJ, Qiu Y, Hewick RM, Wolfman NM. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 2003;17(6):1144-54
   PubMed Web of Science ®Google Scholar
• Amthor H, Nicholas G, McKinnell I, et al. Follistatin complexes myostatin and antagonises myostatin-mediated inhibition of myogenesis. Dev Biol 2004;270(1):19-30
   PubMed Web of Science ®Google Scholar
• Sidis Y, Mukherjee A, Keutmann H, et al. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology 2006;147(7):3586-97
   PubMed Web of Science ®Google Scholar
• Thompson TB. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions. EMBO J 2003;22(7):1555-66
   PubMedGoogle Scholar
• Thompson TB, Lerch TF, Cook RW, et al. The structure of the follistatin: activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 2005;9(4):535-43
   PubMedGoogle Scholar
• Stamler R, Keutmann HT, Sidis Y, et al. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity. J Biol Chem 2008;283(47):32831-8
   PubMedGoogle Scholar
• Cash JN, Angerman EB, Kattamuri C, et al. Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding. J Biol Chem 2012;287(2):1043-53
   PubMedGoogle Scholar
• Groppe J, Greenwald J, Wiater E, et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002;420(6916):636-42
   PubMed Web of Science ®Google Scholar
• Zhang J-L, Qiu L-Y, Kotzsch A, et al. Crystal structure analysis reveals how the chordin family member crossveinless 2 blocks BMP-2 receptor binding. Dev Cell 2008;14(5):739-50
   PubMedGoogle Scholar
• Mendell JR, Sahenk Z, Malik V, et al. A Phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol Ther 2014;23(1):192-201
   PubMedGoogle Scholar
• Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009;39(3):283-96
   PubMed Web of Science ®Google Scholar
• Haidet AM, Rizo L, Handy C, et al. Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. Proc Natl Acad Sci USA 2008;105(11):4318
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Yaden B, Krishnan V, et al. An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential. J Pharmacol Exp Ther 2013;344(3):616-23
   PubMedGoogle Scholar
• Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009;1(6):6ra15-15
   PubMed Web of Science ®Google Scholar
• Attie KM, Borgstein NG, Yang Y, et al. A single ascending-dose study of muscle regulator ace-031 in healthy volunteers. Muscle Nerve 2012;47(3):416-23
   PubMedGoogle Scholar
• Krivickas LS, Walsh R, Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009;39(1):3-9
   PubMed Web of Science ®Google Scholar
• George Carlson C, Bruemmer K, Sesti J, et al. Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse. Muscle Nerve 2011;43(5):694-9
   PubMedGoogle Scholar
• Dumonceaux J, Marie S, Beley C, et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther 2009;18(5):881-7
   Google Scholar
• Pistilli EE, Bogdanovich S, Goncalves MD, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of duchenne muscular dystrophy. Am J Pathol 2011;178(3):1287-97
   PubMed Web of Science ®Google Scholar
• Morine KJ, Bish LT, Pendrak K, et al. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One 2010;5(2):e9176
   Google Scholar
• Leahy DJ, Aukhil I, Erickson HP. 2.0 Å crystal structure of a four-domain segment of human fibronectin encompassing the RGD loop and synergy region. Cell 1996;84(1):155-64
   PubMedGoogle Scholar
• Koide A, Bailey CW, Huang X, Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 1998;284(4):1141-51
   PubMed Web of Science ®Google Scholar
• Koide S, Koide A, Lipovšek D. Target-binding proteins based on the 10th human fibronectin type III domain (10Fn3). Methods Enzymo1 2012;503:135-56
   PubMedGoogle Scholar
• Koide A, Gilbreth RN, Esaki K, et al. High-affinity single-domain binding proteins with a binary-code interface. Proc Natl Acad Sci USA 2007;104(16):6632-7
   PubMedGoogle Scholar
• Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63(5):561-71
   PubMed Web of Science ®Google Scholar
• Bloom L, Calabro V. FN3: a new protein scaffold reaches the clinic. Drug Discov Today 2009;14(19-20):949-55
   PubMedGoogle Scholar
• Tolcher AW, Sweeney CJ, Papadopoulos K, et al. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of vegfr-2 based on a domain of human fibronectin. Clin Cancer Res 2011;17(2):363-71
   PubMed Web of Science ®Google Scholar
• Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel 2011;24(1-2):3-9
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157(2):220-33
   PubMed Web of Science ®Google Scholar
• Zhang L, Rajan V, Lin E, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011;25(5):1653-63
   PubMed Web of Science ®Google Scholar
• Lee YS, Lee SJ. Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2. Proc Natl Acad Sci USA 2013;110(39):E3713-22
   PubMedGoogle Scholar
• Arounleut P, Bialek P, Liang L-F, et al. A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Exp Gerontol 2013;48(9):898-904
   PubMed Web of Science ®Google Scholar
• Lach-Trifilieff E, Minetti GC, Sheppard K, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol 2014;34(4):606-18
   PubMed Web of Science ®Google Scholar
• Sako D, Grinberg AV, Liu J, et al. Characterization of the Ligand Binding Functionality of the Extracellular Domain of Activin Receptor Type IIB. J Biol Chem 2010;285(27):21037-48
   PubMed Web of Science ®Google Scholar
• Lee S-J, Reed LA, Davies MV, et al. Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proc Natl Acad Sci USA 2005;102(50):18117-22
   PubMed Web of Science ®Google Scholar